ClinicalTrials.gg
CompletedNCT00479388Updated Mar 10, 2015Results posted

Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)

A Phase 3 interventional study of Comparator: simvastatin and niacin (+) laropiprant in Primary Hypercholesterolemia and Mixed Dyslipidemia, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2015-03-10.

Primary conditionHypercholesterolemiaRegistry: DyslipidemiasReclassifiedWhy we changed it
Registry
Dyslipidemias — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hypercholesterolemia
Why
  1. The study's listed conditions name Hypercholesterolemia, a narrower term within Dyslipidemias.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,216
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing simvastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. Simvastatin · Hypercholesterolemia.

Enrollment
4th of 49
1,216 · median 240
Started
2007
with 9 others
Phase 3
26 of 50
none open now
Registered
23rd of 50
by date
Lead sponsor
3 of 50
Merck Sharp & Dohme LLC

Among the 50 studies testing simvastatin in Hypercholesterolemia, this one is the 4th largest by enrollment of the 49 interventional ones that give a count, is one of 10 that started in 2007, is one of 26 in phase 3, and was the 23rd registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

None of the 50 studies testing simvastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →

About simvastatin

Simvastatin: first FDA approval 1991 (ZOCOR), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 50 studies testing simvastatin in Hypercholesterolemia as a file.
02

Study summary

This is a 12-Week clinical trial in patients with Primary hypercholesterolemia or mixed dyslipidemia to study the effects of ER niacin/laropiprant on lipids.

03

Conditions studied

  • Primary Hypercholesterolemia
  • Mixed Dyslipidemia

Browse trials for

04

In context

Hypercholesterolemia Reclassified

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

This study's enrollment of 1,216 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.

Browse Hypercholesterolemia studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Compared within Hypercholesterolemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dyslipidemias. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients 18 to 80 years of age with Primary hypercholesterolemia or mixed dyslipidemia
  • Patients will be eligible for the study if their LDL-C values are within protocol specified range and meet other entry criteria

Exclusion criteria

Exclusion Criteria:

  • Patient whose LDL-C values are not within protocol specified range
06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,216 participants (actual)

Study arms

  • Other
    1

    One tablet of ER niacin/ laropiprant (1g) + one tablet of the run-in statin dose, titrating up to ER niacin/laropiprant (2g) at Week 4 for an additional 8 weeks, with no adjustments to the run-in statin dose.

    Drug: niacin (+) laropiprant

  • Active comparator
    2

    Stable dose of simvastatin or atorvastatin (20mg to 40mg) for 12 weeks.

    Drug: Comparator: simvastatin · Drug: Comparator: atorvastatin calcium

Interventions

  • simvastatin (20mg to 40mg) for 12 weeks.

    Also known as: Zocor®

  • Drugniacin (+) laropiprant

    Drug pages: Niacin · MK-0524

    One tablet of ER niacin/ laropiprant (1g); titrating up to ER niacin/laropiprant (2g) at Week 4 for an additional 8 weeks, with no adjustments to the run-in statin dose.

    Also known as: MK0524A

  • atorvastatin calcium (20mg to 40mg) for 12 weeks.

    Also known as: atorvastatin

07

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Week 12

    Time frame: Baseline and 12 Weeks

Secondary outcomes

  1. Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 12

    Time frame: Baseline and 12 Weeks

  2. Percent Change From Baseline in Triglycerides at Week 12

    Time frame: Baseline and 12 Weeks

08

Results

Posted Jul 31, 2009

Participant flow

First Patient In: 30-Jul-2007 Last Patient Last Visit: 10-Jul-2008 Investigators: 161 sites participated: Australia-5; Austria-4; Canada-11; Czech Republic-5; Denmark-4; France-10; Germany-24; Hungary-6; Israel-4; Italy-11; Netherlands-2; Norway-10; Poland-11; Russian Federation-7; South Africa-9; Spain-4; Sweden-17; United States-17

Participant flow — Overall Study
MilestoneER Niacin/Laropiprant + Run-in StatinRun-in Statin Dose Doubled
Started606610
Completed474537
Not completed13273
Withdrew: Adverse event9045
Withdrew: Lost to follow-up02
Withdrew: Protocol violation109
Withdrew: Withdrawal by subject3217

Outcome measures

PrimaryPercent Change From Baseline in Low Density Lipoprotein Cholesterol at Week 12
Time frame:
Baseline and 12 Weeks
Reported as:
Least squares mean · Percent
Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Week 12
PercentER Niacin/Laropiprant + Run-in StatinRun-in Statin Dose Doubled
Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Week 12-10.0 (-12.6 to -7.4)-5.5 (-7.4 to -3.5)
Statistical analysis
  • ER Niacin/Laropiprant + Run-in Statin vs Run-in Statin Dose Doubled · Repeated measures analysis · p = 0.006 · Median difference (final values): -4.5 · 95% CI -7.7 to -1.3Study times: 4, 8 and 12 weeks. Terms: treatment-by-time, gender-by-time, baseline LDL-C-by-time and concomitant statin group-by-time interaction.
SecondaryPercent Change From Baseline in High Density Lipoprotein Cholesterol at Week 12
Time frame:
Baseline and 12 Weeks
Reported as:
Least squares mean · Percent
Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 12
PercentER Niacin/Laropiprant + Run-in StatinRun-in Statin Dose Doubled
Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 1215.8 (13.8 to 17.8)0.2 (-1.1 to 1.4)
Statistical analysis
  • ER Niacin/Laropiprant + Run-in Statin vs Run-in Statin Dose Doubled · Repeated measures analysis · p = <=0.001 · Mean difference (final values): 15.6 · 95% CI 13.4 to 17.9Study times: 4, 8 and 12 weeks. Terms: treatment-by-time, gender-by-time, baseline HDL-C-by-time and concomitant statin group-by-time interaction.
SecondaryPercent Change From Baseline in Triglycerides at Week 12
Time frame:
Baseline and 12 Weeks
Reported as:
Median · Percent
Percent Change From Baseline in Triglycerides at Week 12
PercentER Niacin/Laropiprant + Run-in StatinRun-in Statin Dose Doubled
Percent Change From Baseline in Triglycerides at Week 12-17.6 (-21.0 to -14.2)-4.0 (-7.2 to -0.9)
Statistical analysis
  • ER Niacin/Laropiprant + Run-in Statin vs Run-in Statin Dose Doubled · Repeated measures analysis · p = <=0.001 · Mean difference (final values): -15.4 · 95% CI -19.2 to -11.7ANCOVA model based on Tukey's normalized ranks with term for treatment, gender, concomitant statin group and Tukey's normal score of baseline.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ER Niacin/Laropiprant + Run-in Statin———
Run-in Statin Dose Doubled———
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventER Niacin/Laropiprant + Run-in StatinRun-in Statin Dose Doubled
Acute coronary syndromeCardiac disorders1/6020/609
Acute myocardial infarctionCardiac disorders1/6020/609
Cardiac failure congestiveCardiac disorders1/6020/609
Eye dischargeEye disorders1/6020/609
Non-cardiac chest painGeneral disorders1/6020/609
Drug hypersensitivityImmune system disorders1/6020/609
Acute sinusitisInfections and infestations1/6020/609
Oral herpesImmune system disorders1/6020/609
Wound sepsisInfections and infestations1/6020/609
Brain neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/6020/609
Most frequent other events
Showing 10 of 192
Most frequent other events
EventER Niacin/Laropiprant + Run-in StatinRun-in Statin Dose Doubled
FlushingVascular disorders68/6029/609
PruritusSkin and subcutaneous tissue disorders52/60210/609
NauseaGastrointestinal disorders20/6029/609
DiarrhoeaGastrointestinal disorders16/6024/609
NasopharyngitisInfections and infestations13/60215/609
Abdominal pain upperGastrointestinal disorders12/6024/609
ParaesthesiaNervous system disorders12/6022/609
MyalgiaMusculoskeletal and connective tissue disorders6/60212/609
BronchitisInfections and infestations11/6025/609
RashSkin and subcutaneous tissue disorders11/6020/609

Baseline characteristics

Age, Continuous
Age, Continuous(years)ER Niacin/Laropiprant + Run-in StatinRun-in Statin Dose DoubledTotal
Mean60.4 ± 9.760.6 ± 9.860.5 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)ER Niacin/Laropiprant + Run-in StatinRun-in Statin Dose DoubledTotal
Female304289593
Male302321623
Coronary Heart Disease Risk Category by Goal
Coronary Heart Disease Risk Category by Goal(Participants)ER Niacin/Laropiprant + Run-in StatinRun-in Statin Dose DoubledTotal
Low Risk at Goal272653
Low Risk Not at Goal161430
Multiple Risk at Goal9182173
Multiple Risk Not at Goal9271163
High Risk at Goal143155298
High Risk Not at Goal237262499
Lipid Modification Type/Dose at Run-in
Lipid Modification Type/Dose at Run-in(participants)ER Niacin/Laropiprant + Run-in StatinRun-in Statin Dose DoubledTotal
Simvastatin 10 mg218233451
Simvastatin 20 mg259268527
Atorvastatin 10 mg129109238
Fasting Serum Glucose (FSG)
Fasting Serum Glucose (FSG)(mg/dL)ER Niacin/Laropiprant + Run-in StatinRun-in Statin Dose DoubledTotal
Mean108.3 ± 27.2108.7 ± 27.7108.5 ± 27.4
High-density lipoprotein cholesterol
High-density lipoprotein cholesterol(mg/dL)ER Niacin/Laropiprant + Run-in StatinRun-in Statin Dose DoubledTotal
Mean54.89 ± 14.4554.97 ± 13.9154.93 ± 14.17
Low-density lipoprotein cholesterol
Low-density lipoprotein cholesterol(mg/dL)ER Niacin/Laropiprant + Run-in StatinRun-in Statin Dose DoubledTotal
Mean117.55 ± 28.66115.82 ± 28.37116.68 ± 28.52
Triglycerides (TG)
Triglycerides (TG)(mg/dL)ER Niacin/Laropiprant + Run-in StatinRun-in Statin Dose DoubledTotal
Median136.00 (46.00 to 594.00)124.00 (42.00 to 852.00)130.00 (42.00 to 852.00)
09

Study locations

No study locations are listed for this record.

10

References and documents

Publications

  • Shah S, Ceska R, Gil-Extremera B, Paolini JF, Giezek H, Vandormael K, Mao A, McCrary Sisk C, Maccubbin D. Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract. 2010 May;64(6):727-38. doi: 10.1111/j.1742-1241.2010.02370.x. PubMed 20518948 ↗
  • Bays HE, Shah A, Lin J, Sisk CM, Dong Q, Maccubbin D. Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups. Am J Cardiovasc Drugs. 2012 Jun 1;12(3):197-206. doi: 10.2165/11631530-000000000-00000. PubMed 22500948 ↗
  • Bays H, Shah A, Dong Q, McCrary Sisk C, Maccubbin D. Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups. Int J Clin Pract. 2011 Apr;65(4):436-45. doi: 10.1111/j.1742-1241.2010.02620.x. PubMed 21401833 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2007, a primary completion of Jul 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2009, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2007
First posted
May 28, 2007
Start
Jul 2007
Primary completionActual
Jul 2008
CompletionActual
Oct 2008
Results first posted
Jul 31, 2009
Last update
Mar 10, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00479388
Responsible party
Sponsor
First posted
May 28, 2007
Start date
Jul 2007
Primary completion
Jul 2008
Completion
Oct 2008
Results posted
Jul 31, 2009
Last update
Mar 10, 2015

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Simvastatin · Niacin · MK-0524 · Atorvastatin

Start the discussion